Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Clene Inc. (CLNN)
USD6.09
-0.10 (-1.62%)
US NASDAQ Healthcare Biotechnology
Address
6550 South Millrock Drive 84121
Salt Lake City, UT, US
Salt Lake City, UT, US
CEO
Robert Etherington
Website
clene.com
IPO
2018-10-18
CIK 1822791 ISIN US1856342019
Also trades on
NASDAQ Capital Market · CLNN (USD)
NASDAQ Capital Market · CLNNW (USD)
Description
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| PubCo | TOTAU | 2020-09-10 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD6.09
-0.10 (-1.62%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
499.3K
Beta
0.92
Float Shares
6.59M
Free Float %
65.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.46% | -5.50% | +5.54% | +66.67% | -17.25% | +20.10% | +165.04% | -60.61% | -95.17% | -96.38% | -96.38% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
6.09
Low
50.00
+721.0%
Consensus
50.00
+721.0%
Median
50.00
+721.0%
High
50.00
+721.0%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
50.00
+721.0%
|
Quality scores
Altman Z-Score
-22.93
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-41.5% Q1'26: -81.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+53.3% ★ Q1'26: -710.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-13,831.0% Q1'26: -32,292.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-11,541.5% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+41.8% Q1'26: +32.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.00× Q1'26: -2.67× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
206.0K
est: 200.0K (+3.0%)
|
723.0K
est: 602.6K (+20.0%)
|
473.0K
est: 431.9K (+9.5%)
|
654.0K
est: 442.0K (+48.0%)
|
342.0K
est: 361.7K (-5.5%)
|
200.0K
est: 138.5K (+44.4%)
|
238.4K
158.9K – 317.9K
+72.1% YoY
|
27.07M
1.22M – 52.93M
+11,256.9% YoY
|
165.79M
13.96M – 317.63M
+512.4% YoY
|
300.15M
25.28M – 575.03M
+81.0% YoY
|
457.66M
38.54M – 876.78M
+52.5% YoY
|
| EBITDA |
-16.96M
est: -200.0K (-8,379.0%)
|
-8.34M
est: -602.6K (-1,284.5%)
|
-25.60M
est: -431.9K (-5,828.6%)
|
-43.24M
est: -442.0K (-9,683.0%)
|
-33.69M
est: -361.7K (-9,214.3%)
|
-21.59M
est: -138.5K (-15,487.0%)
|
-238.4K
-317.9K – -158.9K
-72.1% YoY
|
-27.07M
-52.93M – -1.22M
-11,256.9% YoY
|
-165.79M
-317.63M – -13.96M
-512.4% YoY
|
-300.15M
-575.03M – -25.28M
-81.0% YoY
|
-457.66M
-876.78M – -38.54M
-52.5% YoY
|
| EBIT |
-17.92M
est: -200.0K (-8,860.5%)
|
-9.30M
est: -602.6K (-1,443.0%)
|
-26.62M
est: -431.9K (-6,064.5%)
|
-44.95M
est: -442.0K (-10,068.8%)
|
-35.34M
est: -361.7K (-9,669.0%)
|
-23.08M
est: -138.5K (-16,566.4%)
|
-238.4K
-317.9K – -158.9K
-72.1% YoY
|
-27.07M
-52.93M – -1.22M
-11,256.9% YoY
|
-165.79M
-317.63M – -13.96M
-512.4% YoY
|
-300.15M
-575.03M – -25.28M
-81.0% YoY
|
-457.66M
-876.78M – -38.54M
-52.5% YoY
|
| Net Income |
-19.28M
est: -51.46M (+62.5%)
|
-9.74M
est: -82.06M (+88.1%)
|
-29.92M
est: -69.34M (+56.9%)
|
-49.50M
est: -30.46M (-62.5%)
|
-39.40M
est: -43.87M (+10.2%)
|
-26.17M
est: -23.14M (-13.1%)
|
-20.37M
-21.35M – -19.40M
+12.0% YoY
|
-14.24M
-18.22M – -10.25M
+30.1% YoY
|
45.14M
-8.58M – 74.14M
+417.1% YoY
|
52.43M
-9.99M – 114.85M
+16.1% YoY
|
82.07M
-15.64M – 179.77M
+56.5% YoY
|
| SGA |
3.26M
est: 5.48M (-40.5%)
|
18.81M
est: 16.51M (+14.0%)
|
16.16M
est: 11.83M (+36.6%)
|
14.42M
est: 14.79M (-2.5%)
|
13.31M
est: 12.10M (+10.0%)
|
9.23M
est: 4.63M (+99.2%)
|
7.98M
5.32M – 10.64M
+72.1% YoY
|
905.88M
40.71M – 1.77B
+11,256.9% YoY
|
5.55B
467.13M – 10.63B
+512.4% YoY
|
10.04B
845.69M – 19.24B
+81.0% YoY
|
15.31B
1.29B – 29.34B
+52.5% YoY
|
| EPS |
-5.51
est: -7.40 (+25.5%)
|
-3.16
est: -11.80 (+73.2%)
|
-4.69
est: -9.97 (+53.0%)
|
-9.43
est: -4.74 (-99.1%)
|
-5.67
est: -4.45 (-27.4%)
|
-2.65
est: -2.35 (-12.7%)
|
-2.07
-2.17 – -1.97
+11.9% YoY
|
-1.45
-1.85 – -1.04
+30.1% YoY
|
1.82
-0.87 – 7.52
+225.9% YoY
|
5.32
-1.01 – 11.65
+191.7% YoY
|
8.32
-1.59 – 18.23
+56.5% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | D. Boral Capital | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-22.30M
OE per share TTM
-2.32
Owner's Yield
-34.80%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2,616.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
5
Total invested
271.1K
Insider transactions (90d)
8
Beneficial owners (>5%)
14
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chidozie Ugwumba | 28.02M | 19.90% | 28.02M | — | 28.02M | — | IN | United States | 2023-09-11 | ↗ |
| 2 | Opportunity Fund Holdings, L.P. | 17.74M | 9.99% | 17.74M | — | 17.74M | — | PN | Delaware | 2023-06-28 | ↗ |
| 3 | Opportunity, LLC | 17.74M | 9.99% | 17.74M | — | 17.74M | — | OO | Delaware | 2023-06-28 | ↗ |
| 4 | 20-0989306 | 15.98M | 26.80% | 15.98M | — | 15.98M | — | PN | Nevada | 2021-08-06 | ↗ |
| 5 | David J. Matlin | 5.60M | 7.60% | 5.45M | 150.0K | 5.45M | 10.00 | IN | United States | 2023-02-06 | ↗ |
| 6 | Alison Mosca | 5.51M | 8.70% | 86.4K | 5.42M | 86.4K | 5.42M | IN | United States of America | 2022-02-14 | ↗ |
| 7 | David Lisonbee | 4.58M | 7.69% | 4.58M | — | 4.58M | — | IN | United States | 2021-02-12 | ↗ |
| 8 | 4Life Research, LLC | 4.00M | 6.71% | 4.00M | — | 4.00M | — | OO | Utah | 2021-02-12 | ↗ |
| 9 | United Therapeutics Corporation | 3.66M | 5.88% | 3.66M | — | 3.66M | — | CO | Delaware | 2022-01-14 | ↗ |
| 10 | Armistice Capital, LLC | 700.0K | 8.77% | — | 700.0K | — | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 11 | Steven Boyd | 700.0K | 8.77% | — | 700.0K | — | — | HC, IN | Delaware | 2024-11-14 | ↗ |
| 12 | Citadel Advisors Holdings LP | 6.00 | 5.70% | — | 7.59M | — | — | HC, PN | Delaware | 2023-07-03 | ↗ |
| 13 | Periscope Capital Inc. | — | 0.00% | — | — | — | — | FI | Canada | 2021-02-16 | ↗ |
| 14 | Thomas Layton Walton | — | 0.00% | — | — | — | — | IN | — | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
5
-23 vs prev Q
New positions
0
Closed positions
23
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 770.5K +770.5K (+100.0%) | 4.52B +4.5B (+100.0%) | 7.49% +7.492 pp | 4.13% +4.131 pp | USD5.87 +0.0% | 1 qtrs NEW |
| 2 | SCOGGIN MANAGEMENT LP | 275.0K +25.0K (+10.0%) | 1.61M +108.0K (+7.2%) | 2.67% +0.049 pp | 0.25% +0.012 pp | USD5.23 +12.2% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 222.9K +21.9K (+10.9%) | 1.31M +97.6K (+8.1%) | 2.17% +0.057 pp | 0.00% +0.000 pp | USD4.60 +27.6% | 6 qtrs — |
| 4 | BOXER CAPITAL MANAGEMENT, LLC | 199.7K +199.7K (+100.0%) | 1.17M +1.2M (+100.0%) | 1.94% +1.942 pp | 0.26% +0.257 pp | USD5.87 +0.0% | 1 qtrs NEW |
| 5 | ENSIGN PEAK ADVISORS, INC | 114.4K +99.5K (+668.6%) | 671.3K +581.6K (+648.8%) | 1.11% +0.956 pp | 0.00% +0.001 pp | USD5.89 -0.3% | 2 qtrs — |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 82.1K +6.1K (+8.0%) | 481.9K +24.0K (+5.2%) | 0.80% +0.000 pp | 0.00% +0.000 pp | USD4.94 +18.8% | 6 qtrs — |
| 7 | LUNT CAPITAL MANAGEMENT, INC. | 52.3K +— (+0.0%) | 306.8K -8.1K (-2.6%) | 0.51% -0.041 pp | 0.11% -0.006 pp | USD4.35 +34.9% | 6 qtrs — |
| 8 | PEAK6 LLC | 50.0K +50.0K (+100.0%) | 293.6K +293.6K (+100.0%) | 0.49% +0.486 pp | 0.00% +0.001 pp | USD5.87 +0.0% | 1 qtrs NEW |
| 9 | PARSONS CAPITAL MANAGEMENT INC/RI | 37.2K +— (+0.0%) | 218.6K -5.8K (-2.6%) | 0.36% -0.029 pp | 0.01% -0.001 pp | USD5.32 +10.3% | 5 qtrs — |
| 10 | BLACKROCK, INC. | 33.9K +29.7K (+711.6%) | 198.7K +173.6K (+690.7%) | 0.33% +0.285 pp | 0.00% +0.000 pp | USD5.71 +2.8% | 6 qtrs — |
| 11 | STATE STREET CORP | 29.8K +17.3K (+138.4%) | 174.9K +99.6K (+132.3%) | 0.29% +0.159 pp | 0.00% +0.000 pp | USD5.64 +4.1% | 5 qtrs — |
| 12 | MORGAN STANLEY | 20.4K +515.0 (+2.6%) | 119.9K -64.0 (-0.1%) | 0.20% -0.011 pp | 0.00% +0.000 pp | USD4.68 +25.4% | 6 qtrs — |
| 13 | NORTHERN TRUST CORP | 16.1K -659.0 (-3.9%) | 94.8K -6.5K (-6.4%) | 0.16% -0.020 pp | 0.00% +0.000 pp | USD5.04 +16.5% | 6 qtrs — |
| 14 | PENN DAVIS MCFARLAND INC | 11.0K +— (+0.0%) | 64.6K -1.7K (-2.6%) | 0.11% -0.009 pp | 0.01% -0.001 pp | USD3.08 +90.6% | 4 qtrs — |
| 15 | WELLS FARGO & COMPANY/MN | 5.9K +1.7K (+39.6%) | 34.8K +9.2K (+36.0%) | 0.06% +0.013 pp | 0.00% +0.000 pp | USD5.98 -1.8% | 2 qtrs — |
| 16 | JONES FINANCIAL COMPANIES LLLP | 5.0K +— (+0.0%) | 29.4K -50.0 (-0.2%) | 0.05% -0.004 pp | 0.00% +0.000 pp | USD6.03 -2.7% | 2 qtrs — |
| 17 | PNC FINANCIAL SERVICES GROUP, INC. | 2.7K +— (+0.0%) | 16.1K -424.0 (-2.6%) | 0.03% -0.002 pp | 0.00% +0.000 pp | USD6.03 -2.7% | 2 qtrs — |
| 18 | UBS GROUP AG | 2.6K +2.6K (+17,486.7%) | 15.5K +15.4K (+17,105.6%) | 0.03% +0.026 pp | 0.00% +0.000 pp | USD5.86 +0.2% | 6 qtrs — |
| 19 | ATLANTIC PRIVATE WEALTH, LLC | 2.2K +— (+0.0%) | 12.9K -342.0 (-2.6%) | 0.02% -0.002 pp | 0.01% 0.000 pp | USD4.59 +27.9% | 6 qtrs — |
| 20 | ADVISOR GROUP HOLDINGS, INC. | 1.9K +440.0 (+29.6%) | 11.3K +2.7K (+30.7%) | 0.02% +0.003 pp | 0.00% +0.000 pp | USD4.51 +30.2% | 6 qtrs — |
| 21 | GROUP ONE TRADING, L.P. | 686.00 -33.0 (-4.6%) | 4.0K -305.0 (-7.0%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD3.71 +58.2% | 5 qtrs — |
| 22 | SRS CAPITAL ADVISORS, INC. | 570.00 -2.6K (-82.2%) | 3.3K -16.0K (-82.7%) | 0.01% -0.028 pp | 0.00% 0.000 pp | USD5.55 +5.8% | 6 qtrs — |
| 23 | BANK OF AMERICA CORP /DE/ | 122.00 +55.0 (+82.1%) | 716.00 +312.0 (+77.2%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD5.05 +16.2% | 6 qtrs — |
| 24 | MAI CAPITAL MANAGEMENT | 100.00 +— (+0.0%) | 587.00 -16.0 (-2.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD5.31 +10.5% | 5 qtrs — |
| 25 | FMR LLC | 48.00 +47.0 (+4,700.0%) | 282.00 +276.0 (+4,600.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD5.85 +0.3% | 2 qtrs — |
| 26 | SBI SECURITIES CO., LTD. | 25.00 -15.0K (-99.8%) | 147.00 -90.4K (-99.8%) | 0.00% -0.158 pp | 0.00% -0.002 pp | USD5.08 +15.6% | 5 qtrs — |
| 27 | BNP PARIBAS ARBITRAGE, SNC | 23.00 +— (+0.0%) | 135.00 -4.0 (-2.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.26 +37.8% | 6 qtrs — |
| 28 | US BANCORP \DE\ | 20.00 +— (+0.0%) | 117.00 -4.0 (-3.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.55 +29.0% | 6 qtrs — |
| 29 | MARSHALL WACE, LLP | — -22.7K (-100.0%) | — -136.9K (-100.0%) | 0.00% -0.238 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 30 | RENAISSANCE TECHNOLOGIES LLC | — -30.4K (-100.0%) | — -183.4K (-100.0%) | 0.00% -0.320 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 31 | PRINCIPAL SECURITIES, INC. | — -15.0 (-100.0%) | — -90.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 32 | CITIGROUP INC | — -1.0 (-100.0%) | — -6.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 163.2K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 638.6K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 3.0K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 8.2K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 608.09 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.41M | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 3.1K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.7K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 678.29 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 74.74 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
12
Shares acquired
—
Shares disposed
232.2K
Cash buys
—
Cash sales
12.00
Net activity
-232,204
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 72,884 | 6.80 | 495.6K | 198,890 | I | ↗ |
| 2026-05-01 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 5,795 | 6.01 | 34.8K | 271,774 | I | ↗ |
| 2026-04-30 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 5,736 | 6.08 | 34.9K | 277,569 | I | ↗ |
| 2026-04-29 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 12,170 | 5.63 | 68.5K | 283,305 | I | ↗ |
| 2026-04-28 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 1,591 | 5.90 | 9.4K | 295,475 | I | ↗ |
| 2026-04-21 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 61,345 | 6.14 | 376.7K | 297,066 | I | ↗ |
| 2026-04-20 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 4,318 | 6.12 | 26.4K | 358,411 | I | ↗ |
| 2026-04-17 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 25,040 | 6.43 | 161.0K | 362,729 | I | ↗ |
| 2026-04-16 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 7,748 | 6.40 | 49.6K | 387,769 | I | ↗ |
| 2026-04-15 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 6,374 | 6.48 | 41.3K | 395,517 | I | ↗ |
| 2026-04-02 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 24,925 | 4.81 | 119.9K | 401,891 | I | ↗ |
| 2026-04-01 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 4,278 | 4.97 | 21.3K | 426,816 | I | ↗ |
| 2026-03-31 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 67,991 | 4.88 | 331.8K | 431,094 | I | ↗ |
| 2026-03-30 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 15,536 | 5.10 | 79.2K | 499,085 | I | ↗ |
| 2026-03-27 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 17,470 | 4.75 | 83.0K | 514,621 | I | ↗ |
| 2026-03-26 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 5,319 | 5.40 | 28.7K | 532,091 | I | ↗ |
| 2026-03-25 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 7,098 | 5.50 | 39.0K | 537,410 | I | ↗ |
| 2026-03-24 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 5,492 | 5.78 | 31.7K | 544,508 | I | ↗ |
| 2026-02-19 | WILCOX REED N | Director | A-Award | A | stock option | 3,306 | 4.73 | 15.6K | 3,306 | D | ↗ |
| 2026-02-19 | Mosca Alison | Director | A-Award | A | stock option | 4,201 | 4.73 | 19.9K | 4,201 | D | ↗ |
| 2026-02-19 | McLaughlin Vallerie | Director | A-Award | A | stock option | 3,030 | 4.73 | 14.3K | 3,030 | D | ↗ |
| 2026-02-19 | MATLIN DAVID J | Director | A-Award | A | stock option | 5,372 | 4.73 | 25.4K | 5,372 | D | ↗ |
| 2026-02-19 | Kiernan Matthew | Director | A-Award | A | stock option | 2,755 | 4.73 | 13.0K | 2,755 | D | ↗ |
| 2026-02-19 | Jacobovitz Shalom | Director | A-Award | A | stock option | 4,098 | 4.73 | 19.4K | 4,098 | D | ↗ |
| 2026-02-19 | Gay Jonathon | Director | A-Award | A | stock option | 3,271 | 4.73 | 15.5K | 3,271 | D | ↗ |
| 2026-02-19 | Desai Arjun JJ | Director | A-Award | A | stock option | 3,168 | 4.73 | 15.0K | 3,168 | D | ↗ |
| 2026-02-03 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 5,559 | 4.10 | 22.8K | 550,000 | I | ↗ |
| 2026-02-02 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 3,800 | 4.04 | 15.4K | 555,559 | I | ↗ |
| 2026-01-30 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 5,686 | 4.13 | 23.5K | 559,359 | I | ↗ |
| 2026-01-29 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 15,284 | 4.32 | 66.0K | 565,045 | I | ↗ |
| 2026-01-28 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 8,717 | 4.91 | 42.8K | 580,329 | I | ↗ |
| 2026-01-27 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 4,139 | 5.08 | 21.0K | 589,046 | I | ↗ |
| 2026-01-26 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 6,418 | 5.02 | 32.2K | 593,185 | I | ↗ |
| 2026-01-23 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 5,556 | 5.27 | 29.3K | 599,603 | I | ↗ |
| 2026-01-22 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 12,665 | 5.32 | 67.4K | 605,159 | I | ↗ |
| 2026-01-22 | Mortenson Mark | Officer | A-Award | A | stock option | 75,000 | 5.42 | 406.5K | 75,000 | D | ↗ |
| 2026-01-22 | Etherington Robert Dee | Director / Officer | A-Award | A | stock option | 75,000 | 5.42 | 406.5K | 75,000 | D | ↗ |
| 2026-01-22 | BROWN MORGAN R | Officer | A-Award | A | stock option | 35,000 | 5.42 | 189.7K | 35,000 | D | ↗ |
| 2026-01-21 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 12,119 | 5.05 | 61.2K | 617,824 | I | ↗ |
| 2026-01-20 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 12,432 | 4.80 | 59.7K | 629,943 | I | ↗ |
| 2026-01-16 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 7,923 | 5.13 | 40.6K | 642,375 | I | ↗ |
| 2026-01-15 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 12,563 | 5.10 | 64.1K | 650,298 | I | ↗ |
| 2026-01-14 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 19,621 | 5.12 | 100.5K | 662,861 | I | ↗ |
| 2026-01-13 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 26,105 | 4.89 | 127.7K | 682,482 | I | ↗ |
| 2026-01-13 | Mosca Alison | Director | A-Award | A | Series A Warrants (Right to buy) | 20,000 | 6.00 | 120.0K | 20,000 | I | ↗ |
| 2026-01-13 | MATLIN DAVID J | Director | A-Award | A | Warrant (right to buy) | 40,000 | 6.00 | 240.0K | 40,000 | D | ↗ |
| 2026-01-12 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 32,705 | 5.50 | 179.9K | 708,587 | I | ↗ |
| 2026-01-09 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 9,075 | 6.27 | 56.9K | 741,292 | I | ↗ |
| 2026-01-09 | Mosca Alison | Director | J-Other | D | Tranche B Warrants (Right to buy) | 57,219 | 30.00 | 1.72M | 62,500 | I | ↗ |
| 2026-01-08 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 3,195 | 6.09 | 19.5K | 750,367 | I | ↗ |
| 2026-01-07 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 3,938 | 6.29 | 24.8K | 753,562 | I | ↗ |
| 2026-01-06 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 3,111 | 6.04 | 18.8K | 757,500 | I | ↗ |
| 2026-01-05 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 5,869 | 5.87 | 34.5K | 760,611 | I | ↗ |
| 2026-01-02 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 4,015 | 5.73 | 23.0K | 766,480 | I | ↗ |
| 2025-12-31 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 13,095 | 5.81 | 76.1K | 770,495 | I | ↗ |
| 2025-12-30 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 4,138 | 6.03 | 25.0K | 783,590 | I | ↗ |
| 2025-12-29 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 8,096 | 5.95 | 48.2K | 787,728 | I | ↗ |
| 2025-12-26 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 3,350 | 6.32 | 21.2K | 795,824 | I | ↗ |
| 2025-12-24 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 1,490 | 6.27 | 9.3K | 799,174 | I | ↗ |
| 2025-12-23 | Ugwumba Chidozie | 10% Owner | E-ExpireShort | A | Common Stock | 424,358 | 0.00 | 424.36 | 807,495 | I | ↗ |
| 2025-12-22 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 4,367 | 6.54 | 28.6K | 383,201 | I | ↗ |
| 2025-12-19 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 5,582 | 6.45 | 36.0K | 387,568 | I | ↗ |
| 2025-12-18 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 5,816 | 6.33 | 36.8K | 393,150 | I | ↗ |
| 2025-12-17 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 2,884 | 6.61 | 19.1K | 398,966 | I | ↗ |
| 2025-12-16 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 7,030 | 6.31 | 44.4K | 401,850 | I | ↗ |
| 2025-12-15 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 10,580 | 6.49 | 68.7K | 408,880 | I | ↗ |
| 2025-12-12 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 7,603 | 6.79 | 51.6K | 419,460 | I | ↗ |
| 2025-12-11 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 10,907 | 6.81 | 74.3K | 427,063 | I | ↗ |
| 2025-12-10 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 9,921 | 6.42 | 63.7K | 437,970 | I | ↗ |
| 2025-12-09 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 15,031 | 5.95 | 89.4K | 447,891 | I | ↗ |
| 2025-12-08 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 21,463 | 5.70 | 122.3K | 462,922 | I | ↗ |
| 2025-12-05 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 37,235 | 5.94 | 221.2K | 484,385 | I | ↗ |
| 2025-12-04 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 72,748 | 6.73 | 489.6K | 521,620 | I | ↗ |
| 2025-12-03 | Ugwumba Chidozie | 10% Owner | S-Sale | D | Common Stock | 56,577 | 7.86 | 444.7K | 594,368 | I | ↗ |
| 2025-11-13 | WILCOX REED N | Director | A-Award | A | stock option | 1,893 | 7.30 | 13.8K | 1,893 | D | ↗ |
| 2025-11-13 | Mosca Alison | Director | A-Award | A | stock option | 2,887 | 7.30 | 21.1K | 2,887 | D | ↗ |
| 2025-11-13 | McLaughlin Vallerie | Director | A-Award | A | stock option | 2,083 | 7.30 | 15.2K | 2,083 | D | ↗ |
| 2025-11-13 | MATLIN DAVID J | Director | A-Award | A | stock option | 3,692 | 7.30 | 27.0K | 3,692 | D | ↗ |
| 2025-11-13 | Kiernan Matthew | Director | A-Award | A | stock option | 1,893 | 7.30 | 13.8K | 1,893 | D | ↗ |
| 2025-11-13 | Jacobovitz Shalom | Director | A-Award | A | stock option | 2,816 | 7.30 | 20.6K | 2,816 | D | ↗ |
| 2025-11-13 | Gay Jonathon | Director | A-Award | A | stock option | 2,438 | 7.30 | 17.8K | 2,438 | D | ↗ |
| 2025-11-13 | Desai Arjun JJ | Director | A-Award | A | stock option | 2,177 | 7.30 | 15.9K | 2,177 | D | ↗ |
| 2025-09-25 | Mortenson Mark | Officer | A-Award | A | stock option | 40,000 | 6.05 | 242.0K | 40,000 | D | ↗ |
| 2025-09-25 | Etherington Robert Dee | Director / Officer | A-Award | A | stock option | 40,000 | 6.05 | 242.0K | 40,000 | D | ↗ |
| 2025-09-25 | BROWN MORGAN R | Officer | A-Award | A | stock option | 10,000 | 6.05 | 60.5K | 10,000 | D | ↗ |
| 2025-09-18 | Mortenson Mark | Officer | A-Award | A | stock option | 10,000 | 6.32 | 63.2K | 10,000 | D | ↗ |
| 2025-09-18 | Etherington Robert Dee | Director / Officer | A-Award | A | stock option | 10,000 | 6.32 | 63.2K | 10,000 | D | ↗ |
| 2025-09-18 | BROWN MORGAN R | Officer | A-Award | A | stock option | 10,000 | 6.32 | 63.2K | 10,000 | D | ↗ |
| 2025-08-21 | General Resonance LLC | 10% Owner | S-Sale | D | Common Stock | 3,401 | 5.34 | 18.2K | 704,591 | D | ↗ |
| 2025-08-14 | WILCOX REED N | Director | A-Award | A | stock option | 3,720 | 3.60 | 13.4K | 3,720 | D | ↗ |
| 2025-08-14 | Mosca Alison | Director | A-Award | A | stock option | 5,674 | 3.60 | 20.4K | 5,674 | D | ↗ |
| 2025-08-14 | McLaughlin Vallerie | Director | A-Award | A | stock option | 4,092 | 3.60 | 14.7K | 4,092 | D | ↗ |
| 2025-08-14 | MATLIN DAVID J | Director | A-Award | A | stock option | 7,255 | 3.60 | 26.1K | 7,255 | D | ↗ |
| 2025-08-14 | Kiernan Matthew | Director | A-Award | A | stock option | 3,720 | 3.60 | 13.4K | 3,720 | D | ↗ |
| 2025-08-14 | Jacobovitz Shalom | Director | A-Award | A | stock option | 5,534 | 3.60 | 19.9K | 5,534 | D | ↗ |
| 2025-08-14 | Gay Jonathon | Director | A-Award | A | stock option | 4,790 | 3.60 | 17.2K | 4,790 | D | ↗ |
| 2025-08-14 | Desai Arjun JJ | Director | A-Award | A | stock option | 4,278 | 3.60 | 15.4K | 4,278 | D | ↗ |
| 2025-06-04 | General Resonance LLC | 10% Owner | S-Sale | D | Common Stock | 600 | 4.04 | 2.4K | 707,992 | D | ↗ |
| 2025-06-02 | General Resonance LLC | 10% Owner | S-Sale | D | Common Stock | 600 | 4.12 | 2.5K | 708,592 | D | ↗ |
| 2025-05-30 | General Resonance LLC | 10% Owner | S-Sale | D | Common Stock | 410 | 2.80 | 1.1K | 709,192 | D | ↗ |
| 2025-05-29 | General Resonance LLC | 10% Owner | S-Sale | D | Common Stock | 410 | 2.73 | 1.1K | 709,602 | D | ↗ |
| 2025-05-28 | General Resonance LLC | 10% Owner | S-Sale | D | Common Stock | 420 | 2.60 | 1.1K | 710,012 | D | ↗ |
| 2025-05-27 | General Resonance LLC | 10% Owner | S-Sale | D | Common Stock | 420 | 2.45 | 1.0K | 710,432 | D | ↗ |
| 2025-05-22 | WILCOX REED N | Director | A-Award | A | Stock Options (Right to buy) | 1,500 | 2.45 | 3.7K | 1,500 | D | ↗ |
| 2025-05-22 | Mosca Alison | Director | A-Award | A | Stock Options (Right to buy) | 1,500 | 2.45 | 3.7K | 1,500 | D | ↗ |
| 2025-05-22 | McLaughlin Vallerie | Director | A-Award | A | Stock Options (Right to buy) | 1,500 | 2.45 | 3.7K | 1,500 | D | ↗ |
| 2025-05-22 | MATLIN DAVID J | Director | A-Award | A | Stock Options (Right to buy) | 1,500 | 2.45 | 3.7K | 1,500 | D | ↗ |
| 2025-05-22 | Kiernan Matthew | Director | A-Award | A | Stock Options (Right to buy) | 5,236 | 2.45 | 12.8K | 5,236 | D | ↗ |
| 2025-05-22 | Jacobovitz Shalom | Director | A-Award | A | Stock Options (Right to buy) | 7,788 | 2.45 | 19.1K | 7,788 | D | ↗ |
| 2025-05-22 | Gay Jonathon | Director | A-Award | A | Stock Options (Right to buy) | 1,500 | 2.45 | 3.7K | 1,500 | D | ↗ |
| 2025-05-22 | Desai Arjun JJ | Director | A-Award | A | Stock Options (Right to buy) | 1,500 | 2.45 | 3.7K | 1,500 | D | ↗ |
| 2025-03-19 | General Resonance LLC | 10% Owner | S-Sale | D | Common Stock | 1,400 | 4.40 | 6.2K | 710,852 | D | ↗ |
| 2025-03-18 | General Resonance LLC | 10% Owner | S-Sale | D | Common Stock | 1,333 | 4.45 | 5.9K | 712,252 | D | ↗ |
| 2025-02-27 | WILCOX REED N | Director | A-Award | A | Stock Options (Right to buy) | 2,886 | 4.42 | 12.8K | 2,886 | D | ↗ |
| 2025-02-27 | Mosca Alison | Director | A-Award | A | Stock Options (Right to buy) | 4,402 | 4.42 | 19.5K | 4,402 | D | ↗ |
| 2025-02-27 | McLaughlin Vallerie | Director | A-Award | A | Stock Options (Right to buy) | 3,175 | 4.42 | 14.0K | 3,175 | D | ↗ |
| 2025-02-27 | MATLIN DAVID J | Director | A-Award | A | Stock Options (Right to buy) | 5,628 | 4.42 | 24.9K | 5,628 | D | ↗ |
| 2025-02-27 | Kiernan Matthew | Director | A-Award | A | Stock Options (Right to buy) | 2,886 | 4.42 | 12.8K | 2,886 | D | ↗ |
| 2025-02-27 | Jacobovitz Shalom | Director | A-Award | A | Stock Options (Right to buy) | 4,293 | 4.42 | 19.0K | 4,293 | D | ↗ |
| 2025-02-27 | Gay Jonathon | Director | A-Award | A | Stock Options (Right to buy) | 3,716 | 4.42 | 16.4K | 3,716 | D | ↗ |
| 2025-02-27 | Desai Arjun JJ | Director | A-Award | A | Stock Options (Right to buy) | 3,319 | 4.42 | 14.7K | 3,319 | D | ↗ |
| 2025-02-24 | Mortenson Mark | Officer | A-Award | A | Stock Options (Right to buy) | 40,000 | 4.23 | 169.2K | 40,000 | D | ↗ |
| 2025-02-24 | Etherington Robert Dee | Director / Officer | A-Award | A | Stock Options (Right to buy) | 45,000 | 4.23 | 190.4K | 45,000 | D | ↗ |
| 2025-02-24 | BROWN MORGAN R | Officer | A-Award | A | Stock Options (Right to buy) | 20,000 | 4.23 | 84.6K | 20,000 | D | ↗ |
| 2024-12-06 | WILCOX REED N | Director | A-Award | A | Stock Options (Right to buy) | 2,853 | 4.40 | 12.6K | 2,853 | D | ↗ |
| 2024-12-06 | Mosca Alison | Director | A-Award | A | Stock Options (Right to buy) | 4,350 | 4.40 | 19.1K | 4,350 | D | ↗ |
| 2024-12-06 | McLaughlin Vallerie | Director | A-Award | A | Stock Options (Right to buy) | 3,138 | 4.40 | 13.8K | 3,138 | D | ↗ |
| 2024-12-06 | MATLIN DAVID J | Director | A-Award | A | Stock Options (Right to buy) | 5,563 | 4.40 | 24.5K | 5,563 | D | ↗ |
| 2024-12-06 | Kiernan Matthew | Director | A-Award | A | Stock Options (Right to buy) | 2,853 | 4.40 | 12.6K | 2,853 | D | ↗ |
| 2024-12-06 | Jacobovitz Shalom | Director | A-Award | A | Stock Options (Right to buy) | 4,243 | 4.40 | 18.7K | 4,243 | D | ↗ |
| 2024-12-06 | Gay Jonathon | Director | A-Award | A | Stock Options (Right to buy) | 3,673 | 4.40 | 16.2K | 3,673 | D | ↗ |
| 2024-12-06 | Desai Arjun JJ | Director | A-Award | A | Stock Options (Right to buy) | 3,280 | 4.40 | 14.4K | 3,280 | D | ↗ |
| 2024-10-02 | WILCOX REED N | Director | A-Award | A | Stock Options (Right to buy) | 2,559 | 4.89 | 12.5K | 2,559 | D | ↗ |
| 2024-10-02 | Mosca Alison | Director | A-Award | A | Stock Options (Right to buy) | 3,902 | 4.89 | 19.1K | 3,902 | D | ↗ |
| 2024-10-02 | McLaughlin Vallerie | Director | A-Award | A | Stock Options (Right to buy) | 2,815 | 4.89 | 13.8K | 2,815 | D | ↗ |
| 2024-10-02 | MATLIN DAVID J | Director | A-Award | A | Stock Options (Right to buy) | 4,990 | 4.89 | 24.4K | 4,990 | D | ↗ |
| 2024-10-02 | Kiernan Matthew | Director | A-Award | A | Stock Options (Right to buy) | 2,559 | 4.89 | 12.5K | 2,559 | D | ↗ |
| 2024-10-02 | Jacobovitz Shalom | Director | A-Award | A | Stock Options (Right to buy) | 3,806 | 4.89 | 18.6K | 3,806 | D | ↗ |
| 2024-10-02 | Gay Jonathon | Director | A-Award | A | Stock Options (Right to buy) | 3,295 | 4.89 | 16.1K | 3,295 | D | ↗ |
| 2024-10-02 | Desai Arjun JJ | Director | A-Award | A | Stock Options (Right to buy) | 2,943 | 4.89 | 14.4K | 2,943 | D | ↗ |
| 2024-09-30 | Ugwumba Chidozie | 10% Owner | A-Award | A | Warrants (Right to buy) | 424,358 | 4.82 | 2.05M | 424,358 | I | ↗ |
| 2024-09-30 | Mosca Alison | Director | A-Award | A | Common Stock Purchase Warrant (Right to buy) | 159,134 | 4.82 | 767.0K | 159,134 | I | ↗ |
| 2024-09-30 | Mortenson Mark | Officer | A-Award | A | Warrants (Right to buy) | 20,512 | 4.82 | 98.9K | 20,512 | D | ↗ |
| 2024-09-30 | MATLIN DAVID J | Director | P-Purchase | A | Common Stock | 92,307 | 4.75 | 438.5K | 444,491 | D | ↗ |
| 2024-09-30 | Etherington Robert Dee | Director / Officer | A-Award | A | Warrants (Right to buy) | 10,000 | 4.82 | 48.2K | 10,000 | D | ↗ |
| 2024-08-16 | Mortenson Mark | Officer | A-Award | A | Stock Options (Right to buy) | 25,000 | 5.15 | 128.8K | 25,000 | — | ↗ |
| 2024-08-16 | Etherington Robert Dee | Director / Officer | A-Award | A | Stock Options (Right to buy) | 25,000 | 5.15 | 128.8K | 25,000 | — | ↗ |
| 2024-08-16 | BROWN MORGAN R | Officer | A-Award | A | Stock Options (Right to buy) | 10,000 | 5.15 | 51.5K | 10,000 | — | ↗ |
| 2024-07-29 | Etherington Robert Dee | Director / Officer | M-Exempt | A | Stock Options (Right to buy) | 27,320 | 3.00 | 82.0K | 27,319 | — | ↗ |
| 2024-06-07 | WILCOX REED N | Director | A-Award | A | Stock Options (Right to buy) | 33,704 | 0.37 | 12.5K | 33,704 | — | ↗ |
| 2024-06-07 | Mosca Alison | Director | A-Award | A | Stock Options (Right to buy) | 51,399 | 0.37 | 19.0K | 51,399 | — | ↗ |
| 2024-06-07 | Mortenson Mark | Officer | A-Award | A | Stock Options (Right to buy) | 2,000,000 | 0.37 | 740.0K | 2,000,000 | — | ↗ |
| 2024-06-07 | McLaughlin Vallerie | Director | A-Award | A | Stock Options (Right to buy) | 37,074 | 0.37 | 13.7K | 37,074 | — | ↗ |
| 2024-06-07 | MATLIN DAVID J | Director | A-Award | A | Stock Options (Right to buy) | 65,723 | 0.37 | 24.3K | 65,723 | — | ↗ |
| 2024-06-07 | Kiernan Matthew | Director | A-Award | A | Stock Options (Right to buy) | 33,704 | 0.37 | 12.5K | 33,704 | — | ↗ |
| 2024-06-07 | Jacobovitz Shalom | Director | A-Award | A | Stock Options (Right to buy) | 50,135 | 0.37 | 18.5K | 50,135 | — | ↗ |
| 2024-06-07 | Gay Jonathon | Director | A-Award | A | Stock Options (Right to buy) | 43,394 | 0.37 | 16.1K | 43,394 | — | ↗ |
| 2024-06-07 | Etherington Robert Dee | Director / Officer | A-Award | A | Stock Options (Right to buy) | 900,000 | 0.37 | 333.0K | 900,000 | — | ↗ |
| 2024-06-07 | Desai Arjun JJ | Director | A-Award | A | Stock Options (Right to buy) | 38,760 | 0.37 | 14.3K | 38,760 | — | ↗ |
| 2024-06-07 | BROWN MORGAN R | Officer | A-Award | A | Stock Options (Right to buy) | 400,000 | 0.37 | 148.0K | 400,000 | — | ↗ |
| 2024-05-29 | WILCOX REED N | Director | A-Award | A | Stock Options (Right to buy) | 30,000 | 0.37 | 11.1K | 30,000 | — | ↗ |
| 2024-05-29 | Mosca Alison | Director | A-Award | A | Stock Options (Right to buy) | 30,000 | 0.37 | 11.1K | 30,000 | — | ↗ |
| 2024-05-29 | McLaughlin Vallerie | Director | A-Award | A | Stock Options (Right to buy) | 30,000 | 0.37 | 11.1K | 30,000 | — | ↗ |
| 2024-05-29 | MATLIN DAVID J | Director | A-Award | A | Stock Options (Right to buy) | 30,000 | 30,000.00 | 900.00M | 30,000 | — | ↗ |
| 2024-05-29 | Kiernan Matthew | Director | A-Award | A | Stock Options (Right to buy) | 30,000 | 0.37 | 11.1K | 30,000 | — | ↗ |
| 2024-05-29 | Jacobovitz Shalom | Director | A-Award | A | Stock Options (Right to buy) | 30,000 | 0.37 | 11.1K | 30,000 | — | ↗ |
| 2024-05-29 | Gay Jonathon | Director | A-Award | A | Stock Options (Right to buy) | 30,000 | 0.37 | 11.1K | 30,000 | — | ↗ |
| 2024-05-29 | Desai Arjun JJ | Director | A-Award | A | Stock Options (Right to buy) | 30,000 | 0.37 | 11.1K | 30,000 | — | ↗ |
| 2024-05-01 | General Resonance LLC | 10% Owner | S-Sale | D | Common Stock | 13,000 | 0.40 | 5.1K | 15,313,712 | — | ↗ |
| 2024-04-30 | General Resonance LLC | 10% Owner | S-Sale | D | Common Stock | 13,000 | 0.42 | 5.4K | 15,326,712 | — | ↗ |
| 2024-04-24 | General Resonance LLC | 10% Owner | S-Sale | D | Common Stock | 10,000 | 0.33 | 3.3K | 15,349,712 | — | ↗ |
| 2024-04-09 | General Resonance LLC | 10% Owner | S-Sale | D | Common Stock | 7,500 | 0.39 | 2.9K | 15,435,712 | — | ↗ |
| 2024-03-11 | Mosca Alison | Director | A-Award | A | Stock Options (Right to buy) | 44,959 | 0.44 | 19.8K | 44,959 | — | ↗ |
| 2024-03-11 | McLaughlin Vallerie | Director | A-Award | A | Stock Options (Right to buy) | 32,429 | 0.44 | 14.3K | 32,429 | — | ↗ |
| 2024-03-11 | MATLIN DAVID J | Director | A-Award | A | Stock Options (Right to buy) | 57,488 | 0.44 | 25.3K | 57,488 | — | ↗ |
| 2024-03-11 | Kiernan Matthew | Director | A-Award | A | Stock Options (Right to buy) | 29,481 | 0.44 | 13.0K | 29,481 | — | ↗ |
| 2024-03-11 | Jacobovitz Shalom | Director | A-Award | A | Stock Options (Right to buy) | 43,853 | 0.44 | 19.3K | 43,853 | — | ↗ |
| 2024-03-11 | Gay Jonathon | Director | A-Award | A | Stock Options (Right to buy) | 37,957 | 0.44 | 16.7K | 37,957 | — | ↗ |
| 2024-03-11 | Desai Arjun JJ | Director | A-Award | A | Stock Options (Right to buy) | 33,903 | 0.44 | 14.9K | 33,903 | — | ↗ |
| 2023-11-28 | Mosca Alison | Director | A-Award | A | Stock Options (Right to buy) | 43,814 | 0.45 | 19.7K | 43,814 | — | ↗ |
| 2023-11-28 | McLaughlin Vallerie | Director | A-Award | A | Stock Options (Right to buy) | 31,603 | 0.45 | 14.2K | 31,603 | — | ↗ |
| 2023-11-28 | MATLIN DAVID J | Director | A-Award | A | Stock Options (Right to buy) | 56,024 | 0.45 | 25.2K | 56,024 | — | ↗ |
| 2023-11-28 | Kiernan Matthew | Director | A-Award | A | Stock Options (Right to buy) | 28,730 | 0.45 | 12.9K | 28,730 | — | ↗ |
| 2023-11-28 | Jacobovitz Shalom | Director | A-Award | A | Stock Options (Right to buy) | 42,736 | 0.45 | 19.2K | 42,736 | — | ↗ |
| 2023-11-28 | Gay Jonathon | Director | A-Award | A | Stock Options (Right to buy) | 36,990 | 0.45 | 16.6K | 36,990 | — | ↗ |
| 2023-11-28 | Desai Arjun JJ | Director | A-Award | A | Stock Options (Right to buy) | 33,040 | 0.45 | 14.9K | 33,040 | — | ↗ |
| 2023-11-10 | MATLIN DAVID J | Director | P-Purchase | A | Common Stock | 250,002 | 0.41 | 102.5K | 7,043,686 | — | ↗ |
| 2023-09-18 | Stevens John Henry | Director | A-Award | A | Stock Options (Right to buy) | 27,517 | 0.54 | 14.9K | 27,517 | — | ↗ |
| 2023-09-18 | Mosca Alison | Director | A-Award | A | Stock Options (Right to buy) | 36,490 | 0.54 | 19.7K | 36,490 | — | ↗ |
| 2023-09-18 | McLaughlin Vallerie | Director | A-Award | A | Stock Options (Right to buy) | 26,321 | 0.54 | 14.2K | 26,321 | — | ↗ |
| 2023-09-18 | MATLIN DAVID J | Director | A-Award | A | Stock Options (Right to buy) | 46,659 | 0.54 | 25.2K | 46,659 | — | ↗ |
| 2023-09-18 | Kiernan Matthew | Director | — | D | Stock Options (Right to buy) | 45,000 | 0.54 | 24.3K | 0 | — | ↗ |
| 2023-09-18 | Jacobovitz Shalom | Director | A-Award | A | Stock Options (Right to buy) | 35,593 | 0.54 | 19.2K | 35,593 | — | ↗ |
| 2023-09-18 | Gay Jonathon | Director | A-Award | A | Stock Options (Right to buy) | 26,321 | 0.54 | 14.2K | 26,321 | — | ↗ |
| 2023-09-18 | Desai Arjun JJ | Director | — | D | Stock Options (Right to buy) | 45,000 | 0.54 | 24.3K | 0 | — | ↗ |
| 2023-06-29 | Mortenson Mark | Officer | A-Award | A | Stock Options (Right to buy) | 800,000 | 0.90 | 720.0K | 800,000 | — | ↗ |
| 2023-06-29 | Etherington Robert Dee | Director / Officer | A-Award | A | Stock Options (Right to buy) | 900,000 | 0.90 | 810.0K | 900,000 | — | ↗ |
| 2023-06-29 | BROWN MORGAN R | Officer | A-Award | A | Stock Options (Right to buy) | 400,000 | 0.90 | 360.0K | 400,000 | — | ↗ |
| 2023-06-26 | Stevens John Henry | Director | P-Purchase | A | Common Stock | 316,455 | 0.80 | 253.2K | 800,204 | — | ↗ |
| 2023-06-26 | Etherington Robert Dee | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 0.81 | 20.3K | 25,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-3.1K
Shares Outstanding
10.00M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Robert Etherington President and Chief Executive Officer | 508.8K | — | — | 386.2K | — | 38.5K | 933.4K | 41.37% | ↗ |
| 2 | 2025 | Mark Mortenson Chief Science Officer | 412.0K | — | — | 368.4K | — | 29.1K | 809.4K | 45.51% | ↗ |
| 3 | 2025 | Morgan R. Brown Chief Financial Officer | 292.6K | — | — | 163.5K | — | 31.6K | 487.7K | 33.53% | ↗ |
| 4 | 2024 | Robert Etherington President and Chief Executive Officer | 629.2K | 314.6K | — | 385.6K | — | 38.3K | 1.37M | 28.20% | ↗ |
| 5 | 2024 | Mark Mortenson Chief Science Officer | 496.5K | 198.6K | — | 354.6K | — | 29.0K | 1.08M | 32.87% | ↗ |
| 6 | 2024 | Morgan R. Brown Chief Financial Officer | 401.3K | 160.5K | — | 167.4K | — | 31.5K | 760.6K | 22.01% | ↗ |
| 7 | 2023 | Robert Etherington President and Chief Executive Officer | 654.3K | 368.0K | — | 647.3K | — | 37.0K | 1.71M | 37.93% | ↗ |
| 8 | 2023 | Mark Mortenson Chief Science Officer | 516.2K | 185.6K | — | 648.1K | — | 28.1K | 1.38M | 47.03% | ↗ |
| 9 | 2023 | Morgan R. Brown Chief Financial Officer | 417.2K | 137.5K | — | 408.8K | — | 30.1K | 993.7K | 41.14% | ↗ |
| 10 | 2022 | Robert Etherington President and Chief Executive Officer | 560.9K | — | — | 1.59M | — | 30.1K | 2.18M | 72.91% | ↗ |
| 11 | 2022 | Mark Mortenson Chief Science Officer | 453.2K | — | — | 802.5K | — | 29.7K | 1.29M | 62.43% | ↗ |
| 12 | 2022 | Morgan R. Brown Chief Financial Officer | 320.3K | — | — | 813.9K | — | 24.6K | 1.16M | 70.24% | ↗ |
| 13 | 2022 | Dr. Robert Glanzman Chief Medical Officer | 399.9K | — | — | 316.4K | — | 19.3K | 735.5K | 43.01% | ↗ |
| 14 | 2021 | Robert Etherington President and Chief Executive Officer | 510.4K | 280.0K | 8.1K | 4.27M | — | 29.7K | 5.10M | 83.92% | ↗ |
| 15 | 2021 | Robert Etherington Chief Executive Officer | 510.4K | 280.0K | 8.1K | 4.27M | — | 29.7K | 5.10M | 83.92% | ↗ |
| 16 | 2021 | Mark Mortenson Chief Science Officer | 421.9K | 176.8K | 5.1K | 2.01M | — | 29.7K | 2.64M | 76.21% | ↗ |
| 17 | 2021 | Dr. Robert Glanzman Chief Medical Officer | 397.9K | 164.0K | 1.6K | 971.9K | — | 11.5K | 1.55M | 62.93% | ↗ |
| 18 | 2021 | Robert Glanzman Chief Medical Officer | 397.9K | 164.0K | 1.6K | 971.9K | — | 11.5K | 1.55M | 62.93% | ↗ |
| 19 | 2020 | Robert Etherington Chief Executive Officer | 335.0K | 134.0K | — | — | — | 28.6K | 497.6K | 0.00% | ↗ |
| 20 | 2020 | Mark Mortenson Chief Science Officer | 350.0K | 87.5K | — | — | — | 28.6K | 466.1K | 0.00% | ↗ |
| 21 | 2020 | Robert Glanzman Chief Medical Officer | 350.0K | 87.5K | — | — | — | 9.7K | 447.2K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert Etherington | Chief Executive Officer, President & Director | 547.2K | male |
| Mark G. Mortenson | Chief Science Officer | 441.1K | male |
| Morgan R. Brown | Chief Financial Officer | 324.2K | male |
| Michael T. Hotchkin | Chief Development Officer | — | male |
| Mary Anne Mcneil | Head of Human Resources | — | female |
| Jerry Miraglia | General Counsel & Corporate Secretary | — | male |
| Benjamin Greenberg | Head of Medical | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CLNN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
